A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (NCT06018428)
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
🩺 Plain-English Summary (8th-Grade Level)
Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation. Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.
Who can join: Review the eligibility criteria below.
Location: Scottsdale, Arizona — Scottsdale, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- Scottsdale, Arizona — Scottsdale, Arizona
- Fayetteville, Arkansas — Fayetteville, Arkansas
- Hot Springs, Arkansas — Hot Springs, Arkansas
- Encinitas, California — Encinitas, California
- Fountain Valley, California — Fountain Valley, California
- Lomita, California — Lomita, California
- New Haven, Connecticut — New Haven, Connecticut
- Miami, Florida — Miami, Florida
- Tampa, Florida — Tampa, Florida
- Clarksville, Indiana — Clarksville, Indiana
- Bowling Green, Kentucky — Bowling Green, Kentucky
- Burlington, Massachusetts — Burlington, Massachusetts
- Troy, Michigan — Troy, Michigan
- Warren, Michigan — Warren, Michigan
- New York, New York — New York, New York
- New York, New York — New York, New York
- Wilmington, North Carolina — Wilmington, North Carolina
- Bexley, Ohio — Bexley, Ohio
- Clinical Trials — Canton, Ohio
- Mason, Ohio — Mason, Ohio
- Mayfield Heights, Ohio — Mayfield Heights, Ohio
- Portland, Oregon — Portland, Oregon
- Austin, Texas — Austin, Texas
- Frisco, Texas — Frisco, Texas
- Houston, Texas — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alopecia Areata
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Birmingham, Alabama
- A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo — Northridge, California
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) — Northridge, California
- Alopecia Areata Registry — San Francisco, California
- Intralesional Cyclosporine for Alopecia Areata — Sacramento, California
Explore by condition: All Alopecia Areata clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.